Skip to main content
. Author manuscript; available in PMC: 2016 Sep 10.
Published in final edited form as: J Control Release. 2015 Jun 17;213:57–68. doi: 10.1016/j.jconrel.2015.06.018

Figure 5. APIs release from MZC and MZCL IVRs were active in vitro and in vivo.

Figure 5

(a) Eluent from the in vitro release study (days 1, 25, 46 and 94, pooled). The figure represents the mean ± SD of samples from 12 replicate MZCL IVRs with each dilution run in triplicate. (b) Vaginal fluid was collected in swabs from macaques that received MZC or MZCL IVRs (n=8) and placed in 1 mL of saline. Data is for 48h for HIV-1, 7 days for HPV and day17 HSV-2 (with exception of 1 sample which was 48h) swab sample activity. The vertical lines are the IC50 values with 95% confidence intervals. All dilutions from each vaginal swab sample were run in triplicate, and the graph shows mean ± SD.